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Type A insulin resistance (IR) is caused by heterozygous mutations in the insulin receptor gene. It
presents with mild acanthosis nigricans, severe IR, and hyperandrogenism in the absence of obesity or
lipodystrophy. Treatment aims to improve insulin sensitivity and decrease androgens. An adolescent girl
was evaluated for secondary amenorrhea and prominent hirsutism. She had a normal body mass index,
and laboratory testing revealed an elevated LH to FSH ratio (LH 11.6 mIU/mL, FSH 4.2 mIU/mL),
testosterone 96 ng/dL (reference range ,50 ng/dL), free testosterone 2.21 ng/dL (reference range ,1.09 ng/
dL), normal glucose, and HbA1c of 5.6%. She received a diagnosis of polycystic ovary syndrome (PCOS)
and was referred to our Multi-Specialty Adolescent PCOS Program. There, oral glucose tolerance test
showed fasting glucose and insulin of 80 mg/dL and 63.1 mIU/mL, respectively. The 2-hour glucose and
insulin were 199 mg/dL and 1480 mIU/mL, respectively. Because of hyperandrogenism with severe IR,
dysglycemia, and normal lipids, type A IR was considered. Genetic testing revealed a heterozygous
mutation in the insulin receptor gene [c.3095G.A(pGly1032Asp)]. After standard treatment of hirsutism
and hyperinsulinism failed, a trial of GnRH agonist therapy improved hyperandrogenism and reduced
ovarian size while severe IR persisted. We describe an adolescent with type A IR who experienced
resolution of clinical and biochemical hyperandrogenism during GnRH agonist treatment. Given the
patient’s marked reduction in testosterone and hirsutism despite persistent hyperinsulinism, this case
challenges the idea that insulin increases steroidogenesis independently of gonadotropin effect. GnRH
agonist therapy should be considered in the treatment of hyperandrogenism in severe cases of IR.
Copyright © 2019 Endocrine Society
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Type A insulin resistance (IR) is severe IR caused by heterozygous mutations in the insulin
receptor gene. It presents after puberty with acanthosis nigricans, IR, and hyperandrogenism [1].
Hyperandrogenism in type A IR may result from insulin acting as a cogonadotropin directly
increasing androgen synthesis in theca cells via ovarian insulin receptor signaling [2] or indirectly
by increasing GnRH-mediated LH release from the pituitary [3]. Clinical hyperandrogenism is a
concern for patients, yet there are limited data on treatment options in severe IR syndromes. In a
recently published case of type B insulin resistance masquerading as ovarian hyperthecosis,
GnRH agonist treatment curtailed hyperandrogenism without ameliorating diabetes [4].
Similarly, we describe an adolescent patient with type A IR who demonstrated resolution of
hyperandrogenism during GnRH agonist treatment while severe IR persisted. This case
challenges the notion that insulin increases steroidogenesis independently of gonadotropins.
Abbreviations: BMI, body mass index; IGT, impaired glucose tolerance; IR, insulin resistance; OCP, oral contraceptive pill; OGTT,
oral glucose tolerance test; PCOM, polycystic ovarian morphology; PCOS, polycystic ovary syndrome.
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Table provides laboratory and transabdominal ultrasound results for the patient at initial presentation and throughout the treatment course at each of her follow-up visits. The
shaded column demonstrates the initiation of leuprolide at the patient’s 12-mo follow-up visit, and in the columns to the right (13-mo and 17-mo follow-up visits) she continues on
leuprolide treatment. Reference ranges are reported when available based on internal assays.
Abbreviations: DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; 17-OHP, 17-hydroxyprogesterone.

Reproductive markers
Total testosterone, ng/dL
Free testosterone, ng/dL
Androstenedione, ng/dL
DHEA, ng/dL
DHEAS, mg/dL
17-OHP, ng/dL
LH, mIU/mL
FSH mIU/mL
Ovarian volume, cm3
Right ovary
Left ovary
Follicle number per ovary
Right ovary
Left ovary
Follicle number per section
Right ovary
Left ovary
Endometrial thickness, cm
Metabolic markers
Random cortisol, mg/dL
HbA1c, %
OGTT 0-min glucose, mg/dL
OGTT 2-h glucose, mg/dL
OGTT 0-min insulin, mIU/mL
OGTT 2-h insulin, mIU/mL

Initial Presentation

Table 1. Clinical and Laboratory Evaluation of an Adolescent Girl With an Insulin Receptor Gene Mutation
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1. Case Presentation

2. Discussion
We describe a case of an adolescent girl with type A IR whose severe hirsutism and biochemical
hyperandrogenism were successfully managed on GnRH agonist therapy, despite extreme
hyperinsulinemia. Our patient’s dysglycemia and extreme hyperinsulinemia led to genetic
testing, which revealed a mutation in the insulin receptor gene [c.3095G.A(pGly1032Asp)].
Although the direct causality cannot be proven, we suspect the mutation is pathogenic
because it fits the patient’s clinical picture of type A IR and was not present in the
asymptomatic mother’s genetic testing (asymptomatic father not available for testing). The
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A 16-year-old Hispanic–African American girl presented with secondary amenorrhea and
hirsutism. She attained menarche at age nine with normal cycles until age 13, when
menstrual cycles ceased. At age 14, she noticed increased facial hair necessitating daily
waxing of her upper lip and chin. Measurements revealed a normal body mass index (BMI) of
23.7 kg/m2. Physical examination was unremarkable except for an elevated FerrimanGallwey hirsutism score of 24 and mild acanthosis nigricans. After exclusion of other
endocrinopathies, elevated testosterone (Table 1) and secondary amenorrhea led to the diagnosis of polycystic ovary syndrome (PCOS). The patient was subsequently evaluated at the
multispecialty adolescent PCOS program 1 month later. Her testosterone levels continued to
rise, and a transabdominal ultrasound revealed normal ovarian morphology (based on adult
criteria) and no evidence of malignancy. Oral glucose tolerance test (OGTT) showed impaired
glucose tolerance (IGT) and a substantially elevated 2-hour insulin level of 1480 mIU/mL
(Table 1). Despite prominent IR, her lipid profile was favorable. She was prescribed metformin and a course of medroxyprogesterone to induce withdrawal bleeding.
Because of hyperandrogenism with severe IR, dysglycemia, and favorable lipid profile, type
A and type B IR syndromes were considered. Genetic testing revealed a heterozygous mutation
in the insulin receptor gene for a missense variant designated c.3095G.A(pGly1032Asp),
pointing toward the diagnosis of type A IR.
Five months from initial presentation, the patient reported variable metformin adherence.
The medroxyprogesterone challenge had triggered vaginal bleeding for 1 week, but no further
cycles had occurred. Facial hair returned by noon after her morning shave and depilation, so
spironolactone was added to her treatment. Elevated LH and testosterone levels persisted,
and additional androgen levels were measured to rule out other endocrinopathies (Table 1).
Nine months after the initial presentation, she still was nonadherent to metformin, had
not started spironolactone, and was on her second month of oral contraceptive pill (OCP),
which had been started by her primary care physician to induce cyclic bleeding. Hirsutism
remained a major concern, and the patient’s mood had worsened to prominent depression.
Laboratories showed prominent hyperandrogenemia despite OCP therapy (Table 1). Repeat
transabdominal ultrasound revealed an unchanged left ovary and a substantial increase in
right ovarian size that was not attributed to a dominant follicle, recent ovulation, or ovarian
mass. Sonographic findings related to ovarian size (Table 1) now met the definition of
polycystic ovarian morphology (PCOM) based on the recent international guidelines for
PCOS in adults [5]. Twelve months after the initial presentation, the team decided to start
leuprolide 11.25 mg/mo intramuscular injections to improve treatment adherence and
hyperandrogenism while potentially yielding a secondary benefit on insulin resistance.
One month after leuprolide-induced LH suppression (13-month follow-up, Table 1),
dramatic testosterone reduction and hirsutism improvement were noted, but the patient
complained of hot flashes, so OCP was restarted. Seventeen months from initial presentation
(5 months after leuprolide was started), repeat OGTT still showed IGT and severe IR along
with increased HbA1c (Table 1). Ovarian size had decreased substantially in both ovaries, no
longer meeting the definition of PCOM (Table 1). Endometrial thickness was normal and
unchanged (,1.0 cm, Table 1). Of note, the patient had discontinued OCP after only 1 month.
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